Two-thirds reach for paracetamol, though ibuprofen targets the root cause
For generations, the quiet ritual of reaching for a painkiller during menstrual discomfort has unfolded largely on instinct and habit rather than medical knowledge. A sweeping analysis of 211 million supermarket receipts now reveals that two-thirds of period pain sufferers consistently choose paracetamol over ibuprofen — despite ibuprofen's superior ability to address the biological root of cramping. The finding is less an indictment of individual choice than a portrait of a population left without adequate information, affordable options, or a healthcare system that takes their pain seriously.
- Millions are managing menstrual pain with a medication that treats the sensation but not the cause, while the more effective option sits on the same shelf.
- A 32% gap in pain relief purchases between low- and high-income shoppers reveals that for many, the question is not which painkiller to choose, but whether they can afford any at all.
- Half of those who sought medical help for period pain report being dismissed — by partners, by GPs, and by emergency departments — leaving suffering unacknowledged and untreated.
- The average endometriosis diagnosis takes over nine years, with nearly four in ten patients visiting their GP at least ten times before receiving a referral.
- Researchers and clinicians are now calling for clearer public health guidance, earlier preventative use of NSAIDs, and systemic reform in how menstrual pain is recognised and treated.
When period pain strikes, most people reach for the nearest painkiller — and a decade of supermarket data suggests that instinct is quietly failing millions. Researchers from the Universities of Bristol and Nottingham analysed 211 million receipts spanning 2006 to 2015, tracking what people actually buy when cramps arrive. The result: two-thirds chose paracetamol alongside their period products, while only one-third selected ibuprofen.
The distinction matters because the two drugs work very differently. Menstrual cramps are driven by prostaglandins — chemicals that prompt the uterus to contract. Ibuprofen, as a non-steroidal anti-inflammatory drug, reduces prostaglandin production at the source. Paracetamol only dulls the perception of pain, leaving the underlying inflammation untouched. For mild discomfort, it may suffice; for moderate to severe cramps, it frequently does not. Ibuprofen is not suitable for everyone — those with asthma, stomach ulcers, or kidney conditions may need to avoid it — but for the general population, it is the more effective choice.
The data also exposed a sharper inequality beneath the medication question. People in low-income areas were 32% less likely to purchase any pain relief with their period products. For them, the choice was not paracetamol versus ibuprofen — it was pain relief versus none at all.
This sits within a wider pattern of neglect. A 2025 survey of over 3,000 people found that half had experienced dismissal from a healthcare professional or partner when raising concerns about period pain. More than half said their periods negatively affected daily life. The average wait for an endometriosis diagnosis exceeds nine years, with many patients visiting their GP ten or more times before receiving a referral.
Doctors note that taking ibuprofen before pain peaks — rather than after — can meaningfully reduce severity. Heat, naproxen, and hormonal contraception offer further options for those with access to them. But information gaps, cost barriers, and systemic dismissal mean that for many, even the most basic relief remains out of reach. The receipts tell a story not of ignorance, but of a population navigating pain without adequate support.
When period pain hits, most people reach for whatever painkiller is closest. A new analysis of 211 million supermarket receipts spanning a decade reveals the scale of that instinct—and suggests millions are choosing the wrong medication. Researchers from the University of Bristol and University of Nottingham examined shopping patterns between 2006 and 2015, cross-referencing purchases of period products with pain relief to understand what people actually buy when cramps strike. The findings were stark: two-thirds of those buying pain relief alongside tampons and pads chose paracetamol, while only one-third selected ibuprofen. The problem, according to medical experts, is that ibuprofen is significantly more effective for menstrual pain, yet remains the less popular choice.
The reason comes down to how the two drugs work. During a period, the body releases chemicals called prostaglandins, which trigger the uterus to contract—the source of cramping and discomfort. Ibuprofen, classified as a non-steroidal anti-inflammatory drug, actively reduces prostaglandin production, addressing the root cause of the pain. Paracetamol, by contrast, merely dulls the perception of pain without tackling inflammation or prostaglandin levels. For mild symptoms, paracetamol might take the edge off. For moderate to severe cramps, it often falls short. Paracetamol does have a place for those who cannot tolerate NSAIDs due to asthma, stomach ulcers, or kidney problems—but for the general population experiencing period pain, ibuprofen is the more rational choice.
Yet the shopping data tells a different story about what people actually do. Half of all purchases that included both period products and pain relief represented a deliberate pairing—someone buying supplies and medication together, presumably in anticipation of discomfort. Of those purchases, 50% included paracetamol. The researchers note this pattern holds significance beyond individual choice. The data also revealed a stark socio-economic divide: people living in low-income areas were 32 percent less likely to buy any pain relief alongside period products than their higher-income counterparts. Cost, not preference, was the barrier. For millions, the question was not which painkiller works best, but whether they could afford one at all.
This gap in access sits within a broader landscape of inadequate menstrual health care. A 2025 survey by Wellbeing of Women, titled "Just A Period," questioned more than 3,000 people about their experiences. Half reported having seen a healthcare professional about heavy bleeding or period pain. The other half had not—or had sought help and been dismissed. One in four women said a partner had minimized their symptoms. One in six reported dismissal from a male healthcare professional. More than half said their periods negatively impacted their daily lives, yet the system moved slowly to help. The average wait for an endometriosis diagnosis stretches to nine years and four months. Nearly four in ten women visited their GP at least ten times before receiving a referral. More than half had gone to accident and emergency with symptoms, only to be sent home without treatment.
Doctors acknowledge that taking ibuprofen preventatively—before pain begins—can reduce symptom severity by suppressing prostaglandin production before levels spike. There is no harm in this approach for those who tolerate NSAIDs well. Naproxen, another NSAID, offers a similar mechanism. Heat patches and hot water bottles provide non-pharmaceutical relief. For those with particularly severe or debilitating cramps, hormonal contraception can suppress ovulation and reduce prostaglandin production, offering longer-term management. Yet none of these options reach people who cannot afford them, do not know they exist, or whose symptoms are dismissed before they can seek help. The research makes visible what many experience in silence: the scale of untreated or inadequately treated menstrual pain across the population. It also exposes a system gap—millions are buying the wrong medication, not because they lack intelligence, but because they lack information and, in many cases, the resources to access better options. Until that changes, the pattern will likely persist.
Citas Notables
Using shopping data, we can see just how widespread the need for pain relief really is. This kind of evidence helps make menstrual pain visible at a population level.— Dr Anya Skatova, University of Bristol
Ibuprofen reduces the production of prostaglandins by addressing the process driving the pain in the first place, often providing better relief than paracetamol alone.— Dr Giuseppe Aragona, Prescription Doctor
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter which painkiller someone reaches for? They're both pain relief, aren't they?
Not really. Paracetamol numbs the signal your brain receives, but it doesn't stop the thing causing the pain. Ibuprofen actually quiets the chemical process that makes your uterus contract in the first place. One treats the symptom; the other treats the source.
So why are two-thirds of people buying paracetamol if ibuprofen is better?
Most people don't know the difference. They grab what's familiar, what's advertised, what's on the shelf. And if they're poor, they grab what they can afford. The study found people in low-income areas are a third less likely to buy pain relief at all.
That's a choice, though. People could ask a pharmacist.
Could they? The same survey found half of women have had their period pain dismissed by a healthcare professional. If a doctor doesn't take it seriously, why would someone think to ask for advice on medication?
So this is really about the healthcare system failing people.
It's about that, yes. But it's also about information. Millions of people are making a choice in the dark. They don't know ibuprofen works differently. They don't know they could take it before pain starts. They're just reaching for the first thing.
And the socio-economic gap—that's the real story, isn't it?
It's part of it. But the bigger story is that menstrual pain is invisible at a population level. We don't track it. We don't prioritize it. So people suffer in isolation, thinking their experience is normal, when the data shows it's widespread and largely untreated.